J
John Mendelsohn
Researcher at University of Texas at Austin
Publications - 123
Citations - 19695
John Mendelsohn is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Epidermal growth factor & Receptor. The author has an hindex of 68, co-authored 123 publications receiving 19367 citations. Previous affiliations of John Mendelsohn include University of California, San Diego.
Papers
More filters
Journal Article
Recombinant Humanized anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin Against HER2/neu Overexpressing Human Breast Cancer Xenografts
TL;DR: The combination of pac litaxel and rhuMAb HER2 resulted in the highest tumor growth inhibition and had a significantly superior complete tumor regression rate when compared with either paclitaxel or rhu MAb Her2 alone.
Journal Article
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model.
TL;DR: The results of these experiments indicated that C225 was more effective than 225 in inhibiting tumor growth in this model and suggested that the increased capacity of C225 to compete with ligand for binding to the EGFR was responsible for its enhanced in vivo antitumor effect.
Journal ArticleDOI
Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody.
TL;DR: The results suggest that a minor population of high-affinity EGF receptors may be involved in stimulation of A431 cell proliferation, and indicate different mechanisms of growth inhibition of A430 cells by EGF and 528 IgG.
Journal ArticleDOI
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
Jose Baselga,David G. Pfister,M. R. Cooper,R. Cohen,B. Burtness,M. Bos,Gabriella D'Andrea,Andrew D. Seidman,Larry Norton,K. Gunnett,J. Falcey,V. Anderson,H. Waksal,John Mendelsohn +13 more
TL;DR: C225 has dose-dependent pharmacokinetics, and doses that achieve saturation of systemic clearance are well tolerated, and C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.
Book
The Molecular Basis of Cancer
TL;DR: Malignant Transformation Growth and Spread of Cancer Molecular Abnormalities in Specific Malignancies, Molecular Basis of Cancer Therapy, Molecular Transformation, and spread of cancer molecular abnormalities in specific malignancies as mentioned in this paper.